Skip to content

Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies.

Journal of Pharmacology and Experimental Therapeutics February 1, 1996 DOI: 10.1016/s0022-3565(25)12372-0 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational cohort Peer reviewed
Population Age-matched male Holtzman Sprague-Dawley rats (275-300 g)
Interventions 3 saline
Dose 20 mg/kg free base, s.c., twice daily for 4 days
Duration 4-day injection period; recovery periods of 2, 8, 16, 32, and 52 weeks after the final injection
Measures 125I-RTI-55 radioligand binding, autoradiography with 125I-RTI-55
Topics MDMA Serotonin
Key findings MDMA reduced hippocampal and frontal-parietal serotonin uptake sites to 34% and 25% of control levels at 2 weeks, with no effect on striatal dopamine uptake sites. Recovery was partial by 16 weeks and complete only in hippocampus by 52 weeks, following a rostral-caudal gradient across regions. The authors conclude this is consistent with selective serotonergic neurotoxicity of MDMA.

Abstract

In our study, age-matched Holtzman Sprague-Dawley rats (275-300 g) received injections with either saline (0.9%) or 3,4-methylenedioxymethamphetamine (MDMA; 20 mg/kg free base, s.c) twice daily for 4 days and allowed to recover for 2, 8, 16, 32 and 52 wk after the final injection before death. Radioligand binding studies with 125I-RTI-55 to dopamine uptake sites in striatal homogenates showed no effect of MDMA on the density of dopamine uptake sites. In contrast, saturation binding studies with 125I-RTI-55 to 5-HT uptake sites in hippocampal and frontal-parietal homogenates showed a significant reduction in the number of uptake sites at 2 wk after MDMA treatment (34 and 25%, respectively of controls). By 16 wk, a partial recovery in the number of 5-HT uptake sites was observed in both tissues; however, only a full recovery of serotonin uptake sites was observed in hippocampus at the end of 52 wk. In more detailed studies using autoradiography with 125I-RTI-55, recovery of serotonin uptake sites varied from region to region. In particular, recovery of 5-HT uptake sites in cerebral cortex was observed to follow a rostral-caudal gradient. In addition, recovery of 5-HT uptake site in hippocampus also followed a rostral-caudal gradient. Different rates of recovery of 5-HT uptake sites were also observed for cingulate cortex, laterodorsal thalamus and ventromedial hypothalamus. No effect of MDMA was observed over lateral hypothalamus, substantia nigra and ventral tegmental area, or over serotonergic cell bodies such as dorsal raphe and median raphe. In conclusion, our study is consistent with previous studies describing the selective neurotoxicity of MDMA for serotonin neurons and presents evidence showing the rate of recovery of 5-HT uptake sites varies according to region and that recovery of 5-HT uptake sites in neocortex and hippocampus follows a rostral-caudal gradient.

Comparable studies

Other preclinical and animal studies on MDMA, most cited first.

Citations in the library

Explore topics